ABS204
Anti-phospho-PDHE1-A type I (Ser293) Antibody
from rabbit, purified by affinity chromatography
Synonym(s):
Pyruvate dehydrogenase E1 component subunit alpha, somatic form, mitochondrial, PDHE1-A type I
Sign Into View Organizational & Contract Pricing
All Photos(3)
About This Item
UNSPSC Code:
12352203
eCl@ss:
32160702
NACRES:
NA.41
Recommended Products
biological source
rabbit
Quality Level
antibody form
affinity isolated antibody
antibody product type
primary antibodies
clone
polyclonal
purified by
affinity chromatography
species reactivity
human
species reactivity (predicted by homology)
primate (based on 100% sequence homology), zebrafish (based on 100% sequence homology), rat (based on 100% sequence homology), bovine (based on 100% sequence homology), mouse (based on 100% sequence homology)
technique(s)
immunocytochemistry: suitable
immunoprecipitation (IP): suitable
western blot: suitable
NCBI accession no.
UniProt accession no.
shipped in
wet ice
target post-translational modification
phosphorylation (pSer293)
Gene Information
human ... PDHA1(5160)
General description
In many organisms, the pyruvate dehydrogenase (PDH) complex catalyzes the overall, irreversible conversion of pyruvate to acetyl-CoA and CO2 in the aerobic pathway. This complex also serves as a key regulator for cardiac substrate selection. It contains multiple copies of three enzymatic components: pyruvate dehydrogenase (E1 or PDHE1-A type I), dihydrolipoamide acetyltransferase (E2), and lipoamide dehydrogenase (E3). PDH is regulated by both pyruvate dehydrogenase kinase (PDK)-mediated phosphorylation and feedback inhibition.
Specificity
This antibody recognizes PDHE1-A type I phosphorylated at Ser293.
Immunogen
Epitope: Phosphorylated Ser293
KLH-conjugated linear peptide corresponding to human PDHE1-A type I phosphorylated at Ser293.
Application
Detect phospho-PDHE1-A type I (Ser293) using this Anti-phospho-PDHE1-A type I (Ser293) Antibody validated for use in WB, IC & IP.
Immunocytochemistry Analysis: A 1:500 dilution of this antibody from a representative lot detected phospho-PDHE1-A type I (Ser293) in untreated and DCA-treated HEK293 cells.
Research Category
Metabolism
Metabolism
Research Sub Category
Glucose/Glycogen Metabolism
Glucose/Glycogen Metabolism
Quality
Evaluated by Western Blot in DCA untreated and treated HEK293 cell lysates.
Western Blot Analysis: A 1:10,000 dilution of this antibody detected phospho-PDHE1-A type I (Ser293) in untreated and DCA-treated HEK293 cell lysates.
Western Blot Analysis: A 1:10,000 dilution of this antibody detected phospho-PDHE1-A type I (Ser293) in untreated and DCA-treated HEK293 cell lysates.
Target description
~43 kDa observed
Physical form
Affinity purified
Purified rabbit polyclonal in buffer containing 0.1 M Tris-Glycine (pH 7.4), 150 mM NaCl with 0.05% sodium azide.
Storage and Stability
Stable for 1 year at 2-8°C from date of receipt.
Analysis Note
Control
Untreated and DCA-treated HEK293 cell lysates
Untreated and DCA-treated HEK293 cell lysates
Disclaimer
Unless otherwise stated in our catalog or other company documentation accompanying the product(s), our products are intended for research use only and are not to be used for any other purpose, which includes but is not limited to, unauthorized commercial uses, in vitro diagnostic uses, ex vivo or in vivo therapeutic uses or any type of consumption or application to humans or animals.
Not finding the right product?
Try our Product Selector Tool.
Storage Class Code
12 - Non Combustible Liquids
WGK
WGK 1
Flash Point(F)
Not applicable
Flash Point(C)
Not applicable
Certificates of Analysis (COA)
Search for Certificates of Analysis (COA) by entering the products Lot/Batch Number. Lot and Batch Numbers can be found on a product’s label following the words ‘Lot’ or ‘Batch’.
Already Own This Product?
Find documentation for the products that you have recently purchased in the Document Library.
Rami Al Batran et al.
JCI insight, 4(1) (2019-01-11)
Obese individuals are often at risk for nonalcoholic fatty liver disease (NAFLD), insulin resistance, type 2 diabetes (T2D), and cardiovascular diseases such as angina, thereby requiring combination therapies for their comorbidities. Ranolazine is a second-line antianginal agent that also improves
Cyril Corbet et al.
Nature communications, 9(1), 1208-1208 (2018-03-25)
Lactate exchange between glycolytic and oxidative cancer cells is proposed to optimize tumor growth. Blocking lactate uptake through monocarboxylate transporter 1 (MCT1) represents an attractive therapeutic strategy but may stimulate glucose consumption by oxidative cancer cells. We report here that
Yu Liang et al.
Oncogene, 39(2), 469-485 (2019-10-11)
The development of chemoresistance remains a major challenge that accounts for colorectal cancer (CRC) lethality. Dichloroacetate (DCA) was originally used as a metabolic regulator in the treatment of metabolic diseases; here, DCA was assayed to identify the mechanisms underlying the
Ian M Willis et al.
Proceedings of the National Academy of Sciences of the United States of America, 115(48), 12182-12187 (2018-11-16)
As a master negative regulator of RNA polymerase (Pol) III, Maf1 modulates transcription in response to nutrients and stress to balance the production of highly abundant tRNAs, 5S rRNA, and other small noncoding RNAs with cell growth and maintenance. This
Masaki Kajimoto et al.
Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism, 34(3), 514-521 (2014-01-09)
Anesthetics used in infants and children are implicated in the development of neurocognitive disorders. Although propofol induces neuroapoptosis in developing brain, the underlying mechanisms require elucidation and may have an energetic basis. We studied substrate utilization in immature swine anesthetized
Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.
Contact Technical Service